BRCA1 and breast carcinoma: For example, oversampling of BRCA1/2 carriers in the KOHBRA study could have led to bias in the estimates, but limiting the analyses to two hospital-based cohorts (SGBCC and MyBrCa, unselected breast cancer patients) showed no evidence of such bias.